71% of Self-identified Snorers Have Never Consulted a Healthcare Professional
National survey identifies major obstacles to treating snoring and sleep issuesPLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc....
National survey identifies major obstacles to treating snoring and sleep issuesPLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc....
MCLEAN, Va., June 22, 2023 (GLOBE NEWSWIRE) -- Utah Medicaid providers have a modern, efficient system for submitting claims following...
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering...
30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS NetworkBURLINGTON, Mass. and JERUSALEM, June 21, 2023 (GLOBE NEWSWIRE) --...
MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
LONDON--(BUSINESS WIRE)--#advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has...
AdventHealth Orlando performs their first implant of Guardian™ System, revolutionizing cardiac care in Central FloridaEATONTOWN, N.J. and ORLANDO, Fla., June...
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
Todd Macaluso, David Milligan and Joe Kanatzar will be responsible for expanding premier care access for seniors throughout the US...
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its...
PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading CPAP alternative for the...
71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200...
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double...
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...
Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health...
BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
On-Track Start to Fiscal Year with Progress in Advancing Reimbursement Coverage for Medicare Beneficiaries MARLBOROUGH, Mass. BERLIN and YOKNEAM ILLIT, Israel,...
98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published...